Ewa Trębas-Pietraś

Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy

Erkka Valovirta, Thomas Houmann Petersen, Teresa Piotrowska et al. · Journal of Allergy and Clinical Immunology · 2017 · 337 citations · Full text

Life Sciences, Pediatrics, Pharmacotherapy +17

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial

Holger Mosbech, Regina Deckelmann, F. de Blay et al. · Journal of Allergy and Clinical Immunology · 2014 · 282 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Thomas M. File, Donald E. Low, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 196 citations · Full text

Medicine, Infectious Diseases, Pharmacology +13

High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study

U. Wahn, Ludger Klimek, Anna Płoszczuk et al. · Journal of Allergy and Clinical Immunology · 2012 · 78 citations · Full text

Life Sciences, Immunology, Pediatrics +14